Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q1 2018 (← Previous) (Next →)

Filing Date: May 3, 2018

Total Value: $312.7B (100.0% shares, 0.0% debt)

Holdings (8)

CRSP CRISPR Therapeutics AG 67.3%

Value $210.6B Shares 4,606,242 Est. Cost $41.27 Unrealized 0.0%

— Audentes Therapeutics, Inc. 11.6%

Value $36.2B Shares 1,204,615 Est. Cost $17810.00 Unrealized —

— Achaogen, Inc. 5.3%

Value $16.59B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 4.6%

Value $14.42B Shares 2,215,384 Est. Cost $20.09 Unrealized -72.0%

— CymaBay Therapeutics, Inc. 4.4%

Value $13.62B Shares 1,048,601 Est. Cost $9830.00 Unrealized —

— Second Sight Medical Products, Inc. 2.8%

Value $8.627B Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— ImmuneDesign Corp. 2.3%

Value $7.287B Shares 2,208,210 Est. Cost $7580.00 Unrealized —

— Clovis Oncology, Inc. 1.7%

Value $5.378B Shares 101,855 Est. Cost $56000.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	4,606,242	$210.6B	67.3%	$41.27	0.0%	Common Stock	H17182108
—	Audentes Therapeutics, Inc.	1,204,615	$36.2B	11.6%	$17810.00	—	Common Stock	05070R104
—	Achaogen, Inc.	1,281,152	$16.59B	5.3%	$13050.00	—	Common Stock	004449104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$14.42B	4.6%	$20.09	-72.0%	Common Stock	67576A100
—	CymaBay Therapeutics, Inc.	1,048,601	$13.62B	4.4%	$9830.00	—	Common Stock	23257D103
—	Second Sight Medical Products, Inc.	4,492,975	$8.627B	2.8%	$1210.00	—	Common Stock	81362J100
—	ImmuneDesign Corp.	2,208,210	$7.287B	2.3%	$7580.00	—	Common Stock	45252L103
—	Clovis Oncology, Inc.	101,855	$5.378B	1.7%	$56000.00	—	Common Stock	189464100